UK Department for International Development to Spend US$214.5 Million Over Five Years on Public-Private Partnerships to Fight Infectious Diseases
August 23, 2013
The U.K.'s Department for International Development (DfID) plans to invest £138 million ($214.5 million) over the next five years "with nine public-private partnerships to support development of drugs, vaccines, insecticides, diagnostic tools and microbicides, all to prevent, diagnose or treat disease," This Is Guernsey reports (8/22). "Diseases to be targeted include HIV, tuberculosis, malaria, diarrhea and 'neglected' tropical diseases where there are either no treatments available, or they are difficult to use, or where infections have become resistant to existing drugs," according to Public Finance International. The nine partnerships include the Drugs for Neglected Diseases initiative (DNDi), Medicines for Malaria Venture (MMV), Innovative Vector Control Consortium (IVCC), Foundation for Innovative New Diagnostics (FIND), TB Alliance, Aeras, New Products for Diarrhea and Malaria (PATH), International AIDS Vaccine Initiative (IAVI), and International Partnership for Microbicides (IPM), the news service notes (Smulian, 8/23). In a DfID press release, International Development Secretary Justine Greening said, "Working together in product development partnerships, the public and private sectors have a chance to bring together their expertise for the benefit of millions of the world's poorest and most vulnerable people" (8/22).
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)